Mirador Capital Partners LP Increases Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Mirador Capital Partners LP boosted its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 2.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 119,492 shares of the biopharmaceutical company’s stock after purchasing an additional 3,345 shares during the quarter. Mirador Capital Partners LP’s holdings in Celldex Therapeutics were worth $3,020,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Novo Holdings A S increased its holdings in Celldex Therapeutics by 13.4% during the 3rd quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company’s stock worth $32,755,000 after purchasing an additional 113,663 shares during the last quarter. Jennison Associates LLC grew its position in shares of Celldex Therapeutics by 32.0% in the 3rd quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock worth $45,017,000 after acquiring an additional 321,325 shares in the last quarter. Point72 Asset Management L.P. grew its position in shares of Celldex Therapeutics by 51.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock worth $71,725,000 after acquiring an additional 654,194 shares in the last quarter. BNP Paribas Financial Markets boosted its position in Celldex Therapeutics by 293.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 28,181 shares of the biopharmaceutical company’s stock valued at $958,000 after purchasing an additional 21,013 shares during the period. Finally, D. E. Shaw & Co. Inc. boosted its position in Celldex Therapeutics by 47.5% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 845,560 shares of the biopharmaceutical company’s stock valued at $31,294,000 after purchasing an additional 272,389 shares during the period.

Insider Transactions at Celldex Therapeutics

In other news, CEO Anthony S. Marucci acquired 11,500 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were bought at an average price of $26.82 per share, with a total value of $308,430.00. Following the purchase, the chief executive officer now owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. This represents a 39.95 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 3.80% of the company’s stock.

Celldex Therapeutics Price Performance

Shares of Celldex Therapeutics stock opened at $22.62 on Thursday. The business’s fifty day moving average price is $25.92 and its two-hundred day moving average price is $32.08. The company has a market capitalization of $1.50 billion, a P/E ratio of -8.80 and a beta of 1.62. Celldex Therapeutics, Inc. has a 1-year low of $22.47 and a 1-year high of $53.18.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on CLDX. The Goldman Sachs Group began coverage on Celldex Therapeutics in a research report on Monday, September 30th. They set a “neutral” rating and a $45.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research report on Thursday, January 2nd. Wolfe Research lowered Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. HC Wainwright restated a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research report on Thursday, December 19th. Finally, Citigroup started coverage on Celldex Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $70.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $62.25.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.